CD47 and neoplasm: We found that CD47 × PD‐L1 BisAb treatment resulted in robust CD8+ T cell responses, including the induction of tumor‐resident CD8+ T cells that exhibited functionally superior anti‐tumor immunity when compared to anti‐PD‐L1 monotherapy.